Online inquiry

IVTScrip™ mRNA-Human ARHGEF33, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK26817MR)

This product GTTS-WK26817MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF33 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001145451.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 100271715
UniProt ID A8MVX0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF33, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK26817MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18504MR IVTScrip™ mRNA-Human ANKRD18A, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANKRD18A
GTTS-WK16104MR IVTScrip™ mRNA-Human ANKRD18A, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD18A
GTTS-WK13696MR IVTScrip™ mRNA-Human ADAM8, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADAM8
GTTS-WK14630MR IVTScrip™ mRNA-Human ANKRD50, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD50
GTTS-WK0290MR IVTScrip™ mRNA-Human FBLN5, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FBLN5
GTTS-WK13025MR IVTScrip™ mRNA-Human ACIN1, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACIN1
GTTS-WK28013MR IVTScrip™ mRNA-Human ARHGEF2, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARHGEF2
GTTS-WK24133MR IVTScrip™ mRNA-Human ARL11, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARL11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW